
## Isabella Syring

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2365071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. Clinical Epigenetics, 2015, 7, 10.	1.8	77
2	Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. Clinical Cancer Research, 2017, 23, 1829-1840.	3.2	74
3	Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. Molecular Cancer, 2016, 15, 10.	7.9	53
4	The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. American Journal of Cancer Research, 2015, 5, 2799-807.	1.4	31
5	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget, 2016, 7, 23043-23055.	0.8	24
6	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. Clinical Chemistry, 2019, 65, 559-568.	1.5	17
7	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget, 2017, 8, 7964-7976.	0.8	16
8	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. Diagnostic Pathology, 2015, 10, 165.	0.9	11
9	NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival. American Journal of Cancer Research, 2015, 5, 2816-22.	1.4	8
10	The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells. Annals of Diagnostic Pathology, 2018, 34, 18-26.	0.6	4
11	The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer. Anticancer Research, 2017, 37, 6685-6695.	0.5	4